0.0005
-0.0003
(-37.50%)
As of September 21 at 3:51:25 PM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer & Chairman | 88k | -- | 1963 |
| Mr. Paul T. Lehr J.D. | International Exec. Director, Gen. Counsel & Sec. | 448.26k | -- | 1968 |
| Mr. Mohamed Wa'el Ahmed Hashad | CEO & Director | -- | -- | 1963 |
| Ms. Lisa Locklear | Principal Financial Officer & Accounting Officer, Exec. VP and CFO | -- | -- | 1961 |
| Dr. Dan Gincel Ph.D. | Sr. VP of Strategic Collaborations & Scientific Affairs | -- | -- | 1971 |
| Dr. Nataliya Agafonova M.D. | Chief Medical Officer | -- | -- | 1969 |
Longeveron Inc.
Life Science & Technology Park
1951 NW 7th Avenue Suite 520
Miami, FL 33136
United States
- Full Time Employees:
- 19
Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, an allogeneic medicinal signaling cell therapy product isolated from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Corporate Governance
Longeveron Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available